Sinovac Hid CFDA Bribes, SEC Probe From Shareholders, Lawsuit Says

International Pharmaceutical Regulatory Monitor
A A
A class action lawsuit claims that Beijing-based Sinovac Biotech misled shareholders and bribed regulators at the China Food and Drug Administration to expedite its drug and clinical trial applications.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor